News

CVD

Find us here ...

Subscribe to our newsletter

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.

No spam - just the good stuff

More

News

CVD

Alnylam drug shown to reduce blood pressure in Phase 2 trial

Is the ‘skinny jab’ a new longevity drug?

Novel approach can engineer blood vessels

New regenerative stem cell therapy for heart disease shows promise

Bitterroot Bio raises $145m Series A to transform cardiovascular therapeutics

Depression plays role in accelerating biological aging

Unveiling the exposome: How environmental stressors impact cardiovascular health

Flexible e-tattoo can spot early heart disease red flags

Longevity AI partners with Israel’s leading HMO

Find us here ...

Subscribe to our newsletter

More